Biotechnology company Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is the
developer of the drug-delivery platform DehydraTECH(TM). The company’s
innovative technology promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. An article
discussing the company reads, “One of the delivery challenges is the amount of
CBD waste created, because the human body can only absorb a small amount of the
molecules. DehydraTECH is disrupting this cycle by protecting the product
during stomach transit, amplifying intestinal absorption by five to ten times
over traditional methods and enabling the drug to bypass first-pass liver metabolism.
Third-party lab studies have shown a 15- to 20-minute onset of THC effects in
humans when using the edible tech. . . . Products that use the DehydraTECH
drug-delivery platform have been shown to deliver CBD faster than those that
use medium-chain triglyceride oils. A recent study reported a 319% higher CBD
blood concentration at 60 minutes when using the DehydraTECH formulation as
opposed to coconut oil (http://ibn.fm/vCw4v).
Fatty acids used with DehydraTECH have the added benefit of masking the bitter
taste of CBD, allowing a better overall experience for the consumer without the
need for added sugars or chemicals.”
To view the full article, visit http://ibn.fm/47L2x
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive,
patented-delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the United States and Australia for utilization of its
DehydraTECH delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates, more rapid delivery to the bloodstream, and
important taste-masking benefits for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
